These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30511766)

  • 1. Plazomicin: A Next-Generation Aminoglycoside.
    Shaeer KM; Zmarlicka MT; Chahine EB; Piccicacco N; Cho JC
    Pharmacotherapy; 2019 Jan; 39(1):77-93. PubMed ID: 30511766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
    Eljaaly K; Alharbi A; Alshehri S; Ortwine JK; Pogue JM
    Drugs; 2019 Feb; 79(3):243-269. PubMed ID: 30723876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-Daily Plazomicin for Complicated Urinary Tract Infections.
    Wagenlehner FME; Cloutier DJ; Komirenko AS; Cebrik DS; Krause KM; Keepers TR; Connolly LE; Miller LG; Friedland I; Dwyer JP;
    N Engl J Med; 2019 Feb; 380(8):729-740. PubMed ID: 30786187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plazomicin: an investigational therapy for the treatment of urinary tract infections.
    Karaiskos I; Souli M; Giamarellou H
    Expert Opin Investig Drugs; 2015; 24(11):1501-11. PubMed ID: 26419762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections.
    Bilinskaya A; Linder KE; Kuti JL
    Expert Rev Anti Infect Ther; 2020 Aug; 18(8):705-720. PubMed ID: 32319833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
    Connolly LE; Riddle V; Cebrik D; Armstrong ES; Miller LG
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plazomicin: A New Aminoglycoside.
    Saravolatz LD; Stein GE
    Clin Infect Dis; 2020 Feb; 70(4):704-709. PubMed ID: 31328228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
    Zhanel GG; Lawson CD; Zelenitsky S; Findlay B; Schweizer F; Adam H; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Expert Rev Anti Infect Ther; 2012 Apr; 10(4):459-73. PubMed ID: 22512755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae.
    Thwaites M; Hall D; Stoneburner A; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
    Diagn Microbiol Infect Dis; 2018 Dec; 92(4):338-345. PubMed ID: 30097297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance.
    Clark JA; Burgess DS
    Ther Adv Infect Dis; 2020; 7():2049936120952604. PubMed ID: 32953108
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Castanheira M; Davis AP; Mendes RE; Serio AW; Krause KM; Flamm RK
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.
    Castanheira M; Deshpande LM; Woosley LN; Serio AW; Krause KM; Flamm RK
    J Antimicrob Chemother; 2018 Dec; 73(12):3346-3354. PubMed ID: 30219857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales.
    Asempa TE; Kuti JL; Seroogy JD; Komirenko AS; Nicolau DP
    Clin Ther; 2019 Aug; 41(8):1453-1462. PubMed ID: 31248681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of plazomicin against quinolone-resistant gram-negative bacteria isolated from catheter-associated urinary tract infections.
    Abd-Elmonsef MME; Nagla S; Afandy ME; Maxwell SY
    J Chemother; 2021 Nov; 33(7):462-468. PubMed ID: 33810779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.
    Denervaud-Tendon V; Poirel L; Connolly LE; Krause KM; Nordmann P
    J Antimicrob Chemother; 2017 Oct; 72(10):2787-2791. PubMed ID: 29091226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plazomicin (Zemdri) - a new aminoglycoside antibiotic.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):180-182. PubMed ID: 30681656
    [No Abstract]   [Full Text] [Related]  

  • 19. Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes.
    Cox G; Ejim L; Stogios PJ; Koteva K; Bordeleau E; Evdokimova E; Sieron AO; Savchenko A; Serio AW; Krause KM; Wright GD
    ACS Infect Dis; 2018 Jun; 4(6):980-987. PubMed ID: 29634241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.